The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
207 - If only US data is available for a particular disease, is that acceptable by PAAB?
-
In the absence of Canadian data for disease prevalence, PAAB will consider U.S. data providing it is a reasonable representation of the Canadian environment. An example where geography may differ significantly is microbial prevalence and susceptibility. PAAB will base its review of the data on the specific disease state. When deemed appropriate, the data should be based on recent authoritative consensus guidelines, recognized medical texts or primary epidemiology studies. The presentation of the data should clearly indicate the geographic location and date the data was obtained.
